A genetic medicine company creating safe, effective and accessible cures for chronic diseases.

Screen Shot 2017-08-28 at 7.18.20 PM.png

Our Company

Mediphage Bioceuticals is a genetic medicine company spun out of the University of Waterloo in Canada, focused on developing SAFE, EFFECTIVE, and ACCESSIBLE gene delivery platforms to unlock the therapeutic power of personalized, redoseable, genetic medicine.


December, 2015

Mediphage Bioceuticals Inc. was formed as a spin off company from the University of Waterloo in Ontario, Canada.

Seed Round.

March, 2016

Mediphage Bioceuticals closes its seed round of 490K to develop proof of concept and perform early stage efficacy studies.

Concept Testing.

February, 2017

Mediphage Bioceuticals successfully develops its DNA Ministring production and targeting technology. Mediphage also completes early stage concept and efficacy studies.

MARS Toronto.

March, 2017

Mediphage Bioceuticals moves to the MaRS Innovation Center located in Toronto, Ontario. Mediphage Bio is now entering late stage safety and efficacy studies and is beginning to manufacture DNA Ministrings in compliance with cGMP manufacturing practices.



Screen Shot 2017-08-28 at 8.52.21 PM.png

Featured Platform


DNA Ministrings

DNA ministrings (msDNA) are an efficient, customizable, and redosable vector for ex vivo and in vivo gene therapies, CAR-T, and CRISPR therapeutic applications.

msDNA highlights:

- Modular, non-viral minivectors that maintain stability due to linear topology and closed-ends

- Produced in 8 hours from bacteriophage elements in E. coli bacteria

- The only vectors capable of protecting from harmful mutations in the chromosome by selectively inducing cell death upon harmful integration

- No immunostimulatory components to enhance repeated administration

With the highest safety profile across viral and non-viral vectors, DNA ministrings enhance the transition of current genetic engineering technology into true personalized genetic medicine.

To date, we have graduated from Creative Destruction Labs West, Illumina Accelerator, Canada-Chicago Mentorship Program (C2MP), and our home base - JLABS@Toronto at MaRS Toronto. Additionally, our technology has also been featured in Nature/Cell-affiliate journals.



Current Applications

Our msDNA is currently being evaluated by therapeutic development partners using gene therapy, CAR-T, DNA vaccines, iPSCs, CRISPR, and B cell immunotherapy approaches across a variety of applications.

If you are interested in evaluating msDNA with your technology, please contact us at


Our Team


Dr. Roderick Slavcev,

Founder & CEO, HBSc, PhD, MBA, MRSB, C.Biol

  • Associate Professor, Pharmaceutical Sciences

  • Professor, Business & Entrepreneurship School of Pharmacy, University of Waterloo

  • Chartered Biologist, Royal Society of Biology


Nafiseh Nafissi

Senior Scientist, PhD, MSc

  • B.W. Pearson Research Medal (2014)

  • University of Waterloo School of Pharmacy Award of Excellence (2013)

Nafiseh Nafissi Headshot.png

Lee Bowman,

Chief Operations Officer

  • MA - International Relations

  • BMath - Computer Science (Bioinformatics)

Lee Bowman Headshot.png

Advisory Board


Dr. Grant Isaac,
CFO, Cameco


Dr. Sanjay Singh, President & CEO, Temple Therapeutics B.V. Director, BioteCanada


Dr. Michael Naso,
Director R&D, Johnson & Johnson


Dr. Jake Thiessen, Associate Dean and Founder, University of Waterloo, School of Pharmacy (retired)